CORRESP Filing
Ensysce Biosciences, Inc.
Date: April 14, 2026 · CIK: 0001716947 · Accession: 0001493152-26-016449
AI Filing Summary & Sentiment
File numbers found in text: 333-294939
Show Raw Text
CORRESP
1
filename1.htm
Ensysce
Biosciences, Inc.
7946
Ivanhoe Avenue, Suite 201
La
Jolla, California 92037
April
14, 2026
VIA
EDGAR
U.S.
Securities and Exchange Commission
Division
of Corporation Finance
Office
of Life Sciences
100
F Street, NE
Washington,
D.C. 20549
Attention:
Alan Campbell, Esq.
Re:
Ensysce
Biosciences, Inc.
Registration
Statement on Form S-3
SEC
File No. 333-294939
Filed
April 9, 2026
Ladies
and Gentlemen:
Pursuant
to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, Ensysce Biosciences, Inc.
hereby requests that the effective date of the above-referenced Registration Statement be accelerated to 10:00 AM, Eastern Time, on April
15, 2026, or as soon thereafter as is practicable, or at such other time thereafter as our counsel, Troutman Pepper Locke LLP, may request
by telephone. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Troutman
Pepper Locke LLP, by calling Gregory Rubis at (609) 951-4105.
Please
direct any questions or comments concerning this request to Gregory Rubis.
ENSYSCE
BIOSCIENCES, Inc.
By:
/s/
Lynn Kirkpatrick
Name:
Dr.
Lynn Kirkpatrick
Title:
President
and Chief Executive Officer
cc:
Eric
D. Kline, Troutman Pepper Locke LLP
Gregory
Rubis, Troutman Pepper Locke LLP